//July 28, 2022
Dr. Ethan Dmitrovsky leads a national laboratory dedicated solely to biomedical research, and as a physician-scientist and oncologist he can help combat major public health challenges like cancer, HIV/AIDS and emerging health challenges.
He began his oncology training at the National Cancer Institute. Just before joining the Frederick National Laboratory for Cancer Research, he served as provost and executive vice president of the MD Anderson Cancer Center, a top-ranked cancer center in the United States.
The Frederick National Laboratory for Cancer Research is a government-owned, contractor-operated scientific enterprise. Dmitrovsky is also president of Leidos Biomedical Research Inc., the company which operates the laboratory for the National Cancer Institute.
“We fill the gap … we do work that could not readily be done in an academic sphere or biopharmaceutical company,” Dmitrovsky explained on the Leidos website. The laboratory’s structure gives it a distinct ability to bring together local, national and international organizations.
Dmitrovsky was leading the lab when COVID-19 began spreading, and the Frederick National Laboratory was asked to facilitate the first clinical trials of remdesivir to fight the virus.
In partnership with the National Institute of Allergy and Infectious Diseases, the team completed a double-blind, placebo-controlled, randomized trial of remdesivir in more than 1,000 patients in less than three months working with 70 institutions worldwide.